




RealRate

PHARMACEUTICAL 2020

BridgeBio Pharma Inc.
Rank 119 of 358





RealRate

PHARMACEUTICAL 2020

BridgeBio Pharma Inc.
Rank 119 of 358



The relative strengths and weaknesses of BridgeBio Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BridgeBio Pharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 72% points. The greatest weakness of BridgeBio Pharma Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 31% points.

The company's Economic Capital Ratio, given in the ranking table, is 138%, being 102% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	568,622
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	60,385
Liabilities, Non-Current	95,318
Other Assets	57,432
Other Compr. Net Income	28,252
Other Expenses	2,500
Other Liabilities	0
Other Net Income	-22,345
Other Revenues	40,560
Property and Equipment	5,625
Research and Development	209,947
Selling, General and Administrative Expense	94,353

Output Variable	Value in 1000 USD
Assets	631,679
Liabilities	155,703
Expenses	306,800
Revenues	40,560
Stockholders Equity	475,976
Net Income	-288,585
Comprehensive Net Income	-274,459
Economic Capital Ratio	138%